Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE6A | P16499 | 1/20 | 0.36 |
| ▸ | PDE6G | P18545 | 1/20 | 0.36 |
| ▸ | PDE6B | P35913 | 1/20 | 0.36 |
| ▸ | PDE6C | P51160 | 1/20 | 0.36 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7067425 | 0.93 | PPARG (0.41) | MRGPRX4THRBPOLBPPARGPPARA | |
| SCHEMBL7070031 | 0.86 | MAOB (0.43) | THRBPOLBPDE6DPDE5APDE6A | |
| SCHEMBL7072416 | 0.85 | NUDT1 (0.36) | FFAR4 | |
| SCHEMBL7072019 | 0.84 | NR1H2 (0.40) | MRGPRX4PPARGPPARAFFAR1FFAR4 | |
| SCHEMBL7068783 | 0.83 | ALDH1A1 (0.38) | THRBFFAR4 | |
| SCHEMBL7066501 | 0.82 | MAPT (0.43) | THRB | |
| SCHEMBL7072057 | 0.82 | FFAR4 (0.38) | THRBFFAR1FFAR4 | |
| SCHEMBL7072401 | 0.80 | PPARA (0.39) | MRGPRX4PPARGPPARA | |
| SCHEMBL7069935 | 0.80 | FFAR4 (0.36) | FFAR1FFAR4 | |
| SCHEMBL7072687 | 0.79 | PPARA (0.39) | THRBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | MRGPRX4 2396/4885THRB 956/4885POLB 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.